+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Neuropathy Pain Treatment Market 2022-2026

  • PDF Icon

    Report

  • 120 Pages
  • September 2022
  • Region: Global
  • TechNavio
  • ID: 5027240
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The neuropathy pain treatment market is poised to grow by $3.81 bn during 2022-2026, accelerating at a CAGR of 9.18% during the forecast period. The report on the neuropathy pain treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by a focus on the development of novel therapeutics for postherpetic neuralgia.

The neuropathy pain treatment market analysis includes type segment and geographic landscape.

The neuropathy pain treatment market is segmented as below:

By Type

  • Diabetic neuropathy
  • Chemotherapy-induced neuropathy pain
  • Postherpetic neuralgia
  • Others

By Geographical Landscape

  • North America
  • Europe
  • APAC
  • South America
  • The Middle East and Africa
This study identifies the development of topical patches for neuropathy pain treatment change market dynamics as one of the prime reasons driving the neuropathy pain treatment market growth during the next few years. Also, the growing focus on emerging economies and the association between obesity and endocrine disorders will lead to sizable demand in the market.

The report on the neuropathy pain treatment market covers the following areas:

  • Neuropathy pain treatment market sizing
  • Neuropathy pain treatment market forecast
  • Neuropathy pain treatment market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading neuropathy pain treatment market vendors that include Abbott Laboratories, Assertio Therapeutics Inc., Astellas Pharma Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Baxter International Inc., Biogen Inc., Bristol Myers Squibb Co., Dr. Reddys Laboratories Ltd, Eli Lilly and Co., Endo International Plc, GlaxoSmithKline Plc, Johnson and Johnson, Mallinckrodt Plc, Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd, and VistaGen Therapeutics Inc. Also, the neuropathy pain treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Indication
Exhibit 06: Executive Summary - Chart on Incremental Growth
Exhibit 07: Executive Summary - Data Table on Incremental Growth
Exhibit 08: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 09: Parent market
Exhibit 10: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 11: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 12: Market segments
3.3 Market size 2021
3.4 Market outlook: Forecast for 2021-2026
Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
4.1 Five forces summary
Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
4.2 Bargaining power of buyers
Exhibit 18: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026
4.3 Bargaining power of suppliers
Exhibit 19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
4.4 Threat of new entrants
Exhibit 20: Threat of new entrants - Impact of key factors in 2021 and 2026
4.5 Threat of substitutes
Exhibit 21: Threat of substitutes - Impact of key factors in 2021 and 2026
4.6 Threat of rivalry
Exhibit 22: Threat of rivalry - Impact of key factors in 2021 and 2026
4.7 Market condition
Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
5 Market Segmentation by Indication
5.1 Market segments
Exhibit 24: Chart on Indication - Market share 2021-2026 (%)
Exhibit 25: Data Table on Indication - Market share 2021-2026 (%)
5.2 Comparison by Indication
Exhibit 26: Chart on Comparison by Indication
Exhibit 27: Data Table on Comparison by Indication
5.3 Diabetic neuropathy - Market size and forecast 2021-2026
Exhibit 28: Chart on Diabetic neuropathy - Market size and forecast 2021-2026 ($ million)
Exhibit 29: Data Table on Diabetic neuropathy - Market size and forecast 2021-2026 ($ million)
Exhibit 30: Chart on Diabetic neuropathy - Year-over-year growth 2021-2026 (%)
Exhibit 31: Data Table on Diabetic neuropathy - Year-over-year growth 2021-2026 (%)
5.4 Chemotherapy-induced neuropathy pain - Market size and forecast 2021-2026
Exhibit 32: Chart on Chemotherapy-induced neuropathy pain - Market size and forecast 2021-2026 ($ million)
Exhibit 33: Data Table on Chemotherapy-induced neuropathy pain - Market size and forecast 2021-2026 ($ million)
Exhibit 34: Chart on Chemotherapy-induced neuropathy pain - Year-over-year growth 2021-2026 (%)
Exhibit 35: Data Table on Chemotherapy-induced neuropathy pain - Year-over-year growth 2021-2026 (%)
5.5 Postherpetic neuralgia - Market size and forecast 2021-2026
Exhibit 36: Chart on Postherpetic neuralgia - Market size and forecast 2021-2026 ($ million)
Exhibit 37: Data Table on Postherpetic neuralgia - Market size and forecast 2021-2026 ($ million)
Exhibit 38: Chart on Postherpetic neuralgia - Year-over-year growth 2021-2026 (%)
Exhibit 39: Data Table on Postherpetic neuralgia - Year-over-year growth 2021-2026 (%)
5.6 Others - Market size and forecast 2021-2026
Exhibit 40: Chart on Others - Market size and forecast 2021-2026 ($ million)
Exhibit 41: Data Table on Others - Market size and forecast 2021-2026 ($ million)
Exhibit 42: Chart on Others - Year-over-year growth 2021-2026 (%)
Exhibit 43: Data Table on Others - Year-over-year growth 2021-2026 (%)
5.7 Market opportunity by Indication
Exhibit 44: Market opportunity by Indication ($ million)
6 Customer Landscape
6.1 Customer landscape overview
Exhibit 45: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape
7.1 Geographic segmentation
Exhibit 46: Chart on Market share By Geographical Landscape 2021-2026 (%)
Exhibit 47: Data Table on Market share By Geographical Landscape 2021-2026 (%)
7.2 Geographic comparison
Exhibit 48: Chart on Geographic comparison
Exhibit 49: Data Table on Geographic comparison
7.3 North America - Market size and forecast 2021-2026
Exhibit 50: Chart on North America - Market size and forecast 2021-2026 ($ million)
Exhibit 51: Data Table on North America - Market size and forecast 2021-2026 ($ million)
Exhibit 52: Chart on North America - Year-over-year growth 2021-2026 (%)
Exhibit 53: Data Table on North America - Year-over-year growth 2021-2026 (%)
7.4 Europe - Market size and forecast 2021-2026
Exhibit 54: Chart on Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 55: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 56: Chart on Europe - Year-over-year growth 2021-2026 (%)
Exhibit 57: Data Table on Europe - Year-over-year growth 2021-2026 (%)
7.5 APAC - Market size and forecast 2021-2026
Exhibit 58: Chart on APAC - Market size and forecast 2021-2026 ($ million)
Exhibit 59: Data Table on APAC - Market size and forecast 2021-2026 ($ million)
Exhibit 60: Chart on APAC - Year-over-year growth 2021-2026 (%)
Exhibit 61: Data Table on APAC - Year-over-year growth 2021-2026 (%)
7.6 South America - Market size and forecast 2021-2026
Exhibit 62: Chart on South America - Market size and forecast 2021-2026 ($ million)
Exhibit 63: Data Table on South America - Market size and forecast 2021-2026 ($ million)
Exhibit 64: Chart on South America - Year-over-year growth 2021-2026 (%)
Exhibit 65: Data Table on South America - Year-over-year growth 2021-2026 (%)
7.7 Middle East and Africa - Market size and forecast 2021-2026
Exhibit 66: Chart on Middle East and Africa - Market size and forecast 2021-2026 ($ million)
Exhibit 67: Data Table on Middle East and Africa - Market size and forecast 2021-2026 ($ million)
Exhibit 68: Chart on Middle East and Africa - Year-over-year growth 2021-2026 (%)
Exhibit 69: Data Table on Middle East and Africa - Year-over-year growth 2021-2026 (%)
7.8 US - Market size and forecast 2021-2026
Exhibit 70: Chart on US - Market size and forecast 2021-2026 ($ million)
Exhibit 71: Data Table on US - Market size and forecast 2021-2026 ($ million)
Exhibit 72: Chart on US - Year-over-year growth 2021-2026 (%)
Exhibit 73: Data Table on US - Year-over-year growth 2021-2026 (%)
7.9 Germany - Market size and forecast 2021-2026
Exhibit 74: Chart on Germany - Market size and forecast 2021-2026 ($ million)
Exhibit 75: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
Exhibit 76: Chart on Germany - Year-over-year growth 2021-2026 (%)
Exhibit 77: Data Table on Germany - Year-over-year growth 2021-2026 (%)
7.10 UK - Market size and forecast 2021-2026
Exhibit 78: Chart on UK - Market size and forecast 2021-2026 ($ million)
Exhibit 79: Data Table on UK - Market size and forecast 2021-2026 ($ million)
Exhibit 80: Chart on UK - Year-over-year growth 2021-2026 (%)
Exhibit 81: Data Table on UK - Year-over-year growth 2021-2026 (%)
7.11 Canada - Market size and forecast 2021-2026
Exhibit 82: Chart on Canada - Market size and forecast 2021-2026 ($ million)
Exhibit 83: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
Exhibit 84: Chart on Canada - Year-over-year growth 2021-2026 (%)
Exhibit 85: Data Table on Canada - Year-over-year growth 2021-2026 (%)
7.12 India - Market size and forecast 2021-2026
Exhibit 86: Chart on India - Market size and forecast 2021-2026 ($ million)
Exhibit 87: Data Table on India - Market size and forecast 2021-2026 ($ million)
Exhibit 88: Chart on India - Year-over-year growth 2021-2026 (%)
Exhibit 89: Data Table on India - Year-over-year growth 2021-2026 (%)
7.13 Market opportunity By Geographical Landscape
Exhibit 90: Market opportunity By Geographical Landscape ($ million)
8 Drivers, Challenges, and Trends
8.1 Market drivers
8.2 Market challenges
8.3 Impact of drivers and challenges
Exhibit 91: Impact of drivers and challenges in 2021 and 2026
8.4 Market trends
9 Vendor Landscape
9.1 Overview
9.2 Vendor landscape
Exhibit 92: Overview on Criticality of inputs and Factors of differentiation
9.3 Landscape disruption
Exhibit 93: Overview on factors of disruption
9.4 Industry risks
Exhibit 94: Impact of key risks on business
10 Vendor Analysis
10.1 Vendors covered
Exhibit 95: Vendors covered
10.2 Market positioning of vendors
Exhibit 96: Matrix on vendor position and classification
10.3 Abbott Laboratories
Exhibit 97: Abbott Laboratories - Overview
Exhibit 98: Abbott Laboratories - Business segments
Exhibit 99: Abbott Laboratories - Key news
Exhibit 100: Abbott Laboratories - Key offerings
Exhibit 101: Abbott Laboratories - Segment focus
10.4 Assertio Therapeutics Inc.
Exhibit 102: Assertio Therapeutics Inc. - Overview
Exhibit 103: Assertio Therapeutics Inc. - Business segments
Exhibit 104: Assertio Therapeutics Inc. - Key offerings
Exhibit 105: Assertio Therapeutics Inc. - Segment focus
10.5 AstraZeneca Plc
Exhibit 106: AstraZeneca Plc - Overview
Exhibit 107: AstraZeneca Plc - Product / Service
Exhibit 108: AstraZeneca Plc - Key news
Exhibit 109: AstraZeneca Plc - Key offerings
10.6 Baxter International Inc.
Exhibit 110: Baxter International Inc. - Overview
Exhibit 111: Baxter International Inc. - Business segments
Exhibit 112: Baxter International Inc. - Key news
Exhibit 113: Baxter International Inc. - Key offerings
Exhibit 114: Baxter International Inc. - Segment focus
10.7 Dr Reddys Laboratories Ltd
Exhibit 115: Dr Reddys Laboratories Ltd - Overview
Exhibit 116: Dr Reddys Laboratories Ltd - Business segments
Exhibit 117: Dr Reddys Laboratories Ltd - Key offerings
Exhibit 118: Dr Reddys Laboratories Ltd - Segment focus
10.8 Eli Lilly and Co.
Exhibit 119: Eli Lilly and Co. - Overview
Exhibit 120: Eli Lilly and Co. - Product / Service
Exhibit 121: Eli Lilly and Co. - Key offerings
10.9 Endo International Plc
Exhibit 122: Endo International Plc - Overview
Exhibit 123: Endo International Plc - Business segments
Exhibit 124: Endo International Plc - Key news
Exhibit 125: Endo International Plc - Key offerings
Exhibit 126: Endo International Plc - Segment focus
10.10 Johnson and Johnson
Exhibit 127: Johnson and Johnson - Overview
Exhibit 128: Johnson and Johnson - Business segments
Exhibit 129: Johnson and Johnson - Key news
Exhibit 130: Johnson and Johnson - Key offerings
Exhibit 131: Johnson and Johnson - Segment focus
10.11 Pfizer Inc.
Exhibit 132: Pfizer Inc. - Overview
Exhibit 133: Pfizer Inc. - Product / Service
Exhibit 134: Pfizer Inc. - Key news
Exhibit 135: Pfizer Inc. - Key offerings
10.12 Sanofi SA
Exhibit 136: Sanofi SA - Overview
Exhibit 137: Sanofi SA - Business segments
Exhibit 138: Sanofi SA - Key news
Exhibit 139: Sanofi SA - Key offerings
Exhibit 140: Sanofi SA - Segment focus
11 Appendix
11.1 Scope of the report
11.2 Inclusions and exclusions checklist
Exhibit 141: Inclusions checklist
Exhibit 142: Exclusions checklist
11.3 Currency conversion rates for US$
Exhibit 143: Currency conversion rates for US$
11.4 Research methodology
Exhibit 144: Research methodology
Exhibit 145: Validation techniques employed for market sizing
Exhibit 146: Information sources
11.5 List of abbreviations
Exhibit 147: List of abbreviations
List of Exhibits
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by Indication
Exhibits 6: Executive Summary - Chart on Incremental Growth
Exhibits 7: Executive Summary - Data Table on Incremental Growth
Exhibits 8: Executive Summary - Chart on Vendor Market Positioning
Exhibits 9: Parent market
Exhibits 10: Market Characteristics
Exhibits 11: Offerings of vendors included in the market definition
Exhibits 12: Market segments
Exhibits 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
Exhibits 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
Exhibits 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
Exhibits 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
Exhibits 17: Five forces analysis - Comparison between 2021 and 2026
Exhibits 18: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026
Exhibits 19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
Exhibits 20: Threat of new entrants - Impact of key factors in 2021 and 2026
Exhibits 21: Threat of substitutes - Impact of key factors in 2021 and 2026
Exhibits 22: Threat of rivalry - Impact of key factors in 2021 and 2026
Exhibits 23: Chart on Market condition - Five forces 2021 and 2026
Exhibits 24: Chart on Indication - Market share 2021-2026 (%)
Exhibits 25: Data Table on Indication - Market share 2021-2026 (%)
Exhibits 26: Chart on Comparison by Indication
Exhibits 27: Data Table on Comparison by Indication
Exhibits 28: Chart on Diabetic neuropathy - Market size and forecast 2021-2026 ($ million)
Exhibits 29: Data Table on Diabetic neuropathy - Market size and forecast 2021-2026 ($ million)
Exhibits 30: Chart on Diabetic neuropathy - Year-over-year growth 2021-2026 (%)
Exhibits 31: Data Table on Diabetic neuropathy - Year-over-year growth 2021-2026 (%)
Exhibits 32: Chart on Chemotherapy-induced neuropathy pain - Market size and forecast 2021-2026 ($ million)
Exhibits 33: Data Table on Chemotherapy-induced neuropathy pain - Market size and forecast 2021-2026 ($ million)
Exhibits 34: Chart on Chemotherapy-induced neuropathy pain - Year-over-year growth 2021-2026 (%)
Exhibits 35: Data Table on Chemotherapy-induced neuropathy pain - Year-over-year growth 2021-2026 (%)
Exhibits 36: Chart on Postherpetic neuralgia - Market size and forecast 2021-2026 ($ million)
Exhibits 37: Data Table on Postherpetic neuralgia - Market size and forecast 2021-2026 ($ million)
Exhibits 38: Chart on Postherpetic neuralgia - Year-over-year growth 2021-2026 (%)
Exhibits 39: Data Table on Postherpetic neuralgia - Year-over-year growth 2021-2026 (%)
Exhibits 40: Chart on Others - Market size and forecast 2021-2026 ($ million)
Exhibits 41: Data Table on Others - Market size and forecast 2021-2026 ($ million)
Exhibits 42: Chart on Others - Year-over-year growth 2021-2026 (%)
Exhibits 43: Data Table on Others - Year-over-year growth 2021-2026 (%)
Exhibits 44: Market opportunity by Indication ($ million)
Exhibits 45: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 46: Chart on Market share By Geographical Landscape 2021-2026 (%)
Exhibits 47: Data Table on Market share By Geographical Landscape 2021-2026 (%)
Exhibits 48: Chart on Geographic comparison
Exhibits 49: Data Table on Geographic comparison
Exhibits 50: Chart on North America - Market size and forecast 2021-2026 ($ million)
Exhibits 51: Data Table on North America - Market size and forecast 2021-2026 ($ million)
Exhibits 52: Chart on North America - Year-over-year growth 2021-2026 (%)
Exhibits 53: Data Table on North America - Year-over-year growth 2021-2026 (%)
Exhibits 54: Chart on Europe - Market size and forecast 2021-2026 ($ million)
Exhibits 55: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
Exhibits 56: Chart on Europe - Year-over-year growth 2021-2026 (%)
Exhibits 57: Data Table on Europe - Year-over-year growth 2021-2026 (%)
Exhibits 58: Chart on APAC - Market size and forecast 2021-2026 ($ million)
Exhibits 59: Data Table on APAC - Market size and forecast 2021-2026 ($ million)
Exhibits 60: Chart on APAC - Year-over-year growth 2021-2026 (%)
Exhibits 61: Data Table on APAC - Year-over-year growth 2021-2026 (%)
Exhibits 62: Chart on South America - Market size and forecast 2021-2026 ($ million)
Exhibits 63: Data Table on South America - Market size and forecast 2021-2026 ($ million)
Exhibits 64: Chart on South America - Year-over-year growth 2021-2026 (%)
Exhibits 65: Data Table on South America - Year-over-year growth 2021-2026 (%)
Exhibits 66: Chart on Middle East and Africa - Market size and forecast 2021-2026 ($ million)
Exhibits 67: Data Table on Middle East and Africa - Market size and forecast 2021-2026 ($ million)
Exhibits 68: Chart on Middle East and Africa - Year-over-year growth 2021-2026 (%)
Exhibits 69: Data Table on Middle East and Africa - Year-over-year growth 2021-2026 (%)
Exhibits 70: Chart on US - Market size and forecast 2021-2026 ($ million)
Exhibits 71: Data Table on US - Market size and forecast 2021-2026 ($ million)
Exhibits 72: Chart on US - Year-over-year growth 2021-2026 (%)
Exhibits 73: Data Table on US - Year-over-year growth 2021-2026 (%)
Exhibits 74: Chart on Germany - Market size and forecast 2021-2026 ($ million)
Exhibits 75: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
Exhibits 76: Chart on Germany - Year-over-year growth 2021-2026 (%)
Exhibits 77: Data Table on Germany - Year-over-year growth 2021-2026 (%)
Exhibits 78: Chart on UK - Market size and forecast 2021-2026 ($ million)
Exhibits 79: Data Table on UK - Market size and forecast 2021-2026 ($ million)
Exhibits 80: Chart on UK - Year-over-year growth 2021-2026 (%)
Exhibits 81: Data Table on UK - Year-over-year growth 2021-2026 (%)
Exhibits 82: Chart on Canada - Market size and forecast 2021-2026 ($ million)
Exhibits 83: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
Exhibits 84: Chart on Canada - Year-over-year growth 2021-2026 (%)
Exhibits 85: Data Table on Canada - Year-over-year growth 2021-2026 (%)
Exhibits 86: Chart on India - Market size and forecast 2021-2026 ($ million)
Exhibits 87: Data Table on India - Market size and forecast 2021-2026 ($ million)
Exhibits 88: Chart on India - Year-over-year growth 2021-2026 (%)
Exhibits 89: Data Table on India - Year-over-year growth 2021-2026 (%)
Exhibits 90: Market opportunity By Geographical Landscape ($ million)
Exhibits 91: Impact of drivers and challenges in 2021 and 2026
Exhibits 92: Overview on Criticality of inputs and Factors of differentiation
Exhibits 93: Overview on factors of disruption
Exhibits 94: Impact of key risks on business
Exhibits 95: Vendors covered
Exhibits 96: Matrix on vendor position and classification
Exhibits 97: Abbott Laboratories - Overview
Exhibits 98: Abbott Laboratories - Business segments
Exhibits 99: Abbott Laboratories - Key news
Exhibits 100: Abbott Laboratories - Key offerings
Exhibits 101: Abbott Laboratories - Segment focus
Exhibits 102: Assertio Therapeutics Inc. - Overview
Exhibits 103: Assertio Therapeutics Inc. - Business segments
Exhibits 104: Assertio Therapeutics Inc. - Key offerings
Exhibits 105: Assertio Therapeutics Inc. - Segment focus
Exhibits 106: AstraZeneca Plc - Overview
Exhibits 107: AstraZeneca Plc - Product / Service
Exhibits 108: AstraZeneca Plc - Key news
Exhibits 109: AstraZeneca Plc - Key offerings
Exhibits 110: Baxter International Inc. - Overview
Exhibits 111: Baxter International Inc. - Business segments
Exhibits 112: Baxter International Inc. - Key news
Exhibits 113: Baxter International Inc. - Key offerings
Exhibits 114: Baxter International Inc. - Segment focus
Exhibits 115: Dr Reddys Laboratories Ltd - Overview
Exhibits 116: Dr Reddys Laboratories Ltd - Business segments
Exhibits 117: Dr Reddys Laboratories Ltd - Key offerings
Exhibits 118: Dr Reddys Laboratories Ltd - Segment focus
Exhibits 119: Eli Lilly and Co. - Overview
Exhibits 120: Eli Lilly and Co. - Product / Service
Exhibits 121: Eli Lilly and Co. - Key offerings
Exhibits 122: Endo International Plc - Overview
Exhibits 123: Endo International Plc - Business segments
Exhibits 124: Endo International Plc - Key news
Exhibits 125: Endo International Plc - Key offerings
Exhibits 126: Endo International Plc - Segment focus
Exhibits 127: Johnson and Johnson - Overview
Exhibits 128: Johnson and Johnson - Business segments
Exhibits 129: Johnson and Johnson - Key news
Exhibits 130: Johnson and Johnson - Key offerings
Exhibits 131: Johnson and Johnson - Segment focus
Exhibits 132: Pfizer Inc. - Overview
Exhibits 133: Pfizer Inc. - Product / Service
Exhibits 134: Pfizer Inc. - Key news
Exhibits 135: Pfizer Inc. - Key offerings
Exhibits 136: Sanofi SA - Overview
Exhibits 137: Sanofi SA - Business segments
Exhibits 138: Sanofi SA - Key news
Exhibits 139: Sanofi SA - Key offerings
Exhibits 140: Sanofi SA - Segment focus
Exhibits 141: Inclusions checklist
Exhibits 142: Exclusions checklist
Exhibits 143: Currency conversion rates for US$
Exhibits 144: Research methodology
Exhibits 145: Validation techniques employed for market sizing
Exhibits 146: Information sources
Exhibits 147: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global neuropathy pain treatment market: Abbott Laboratories, Assertio Therapeutics Inc., Astellas Pharma Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Baxter International Inc., Biogen Inc., Bristol Myers Squibb Co., Dr. Reddys Laboratories Ltd, Eli Lilly and Co., Endo International Plc, GlaxoSmithKline Plc, Johnson and Johnson, Mallinckrodt Plc, Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd, and VistaGen Therapeutics Inc.

Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is the development of topical patches for neuropathy pain treatment change market dynamics.`

According to the report, one of the major drivers for this market is the focus on the development of novel therapeutics for postherpetic neuralgia.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott Laboratories
  • Assertio Therapeutics Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Aurobindo Pharma Ltd.
  • Baxter International Inc.
  • Biogen Inc.
  • Bristol Myers Squibb Co.
  • Dr Reddys Laboratories Ltd
  • Eli Lilly and Co.
  • Endo International Plc
  • GlaxoSmithKline Plc
  • Johnson and Johnson
  • Mallinckrodt Plc
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd
  • VistaGen Therapeutics Inc.